Host Cell Proteins in Biologics Development: Why Monitoring Matters

Introduction

Host cell proteins (HCPs) are an unavoidable part of biologics production. During expression in systems such as CHO cells, a wide range of endogenous proteins are released alongside the target product.

While most of these impurities are removed during downstream processing, residual HCPs remain a key consideration throughout development. Monitoring them is not just a regulatory requirement—it plays an important role in process understanding, optimisation, and product quality.

What Are Host Cell Proteins?

Host cell proteins are proteins derived from the expression system used to produce a biologic, such as:

CHO cells
HEK293 cells
Microbial systems (e.g. E. coli)

They can originate from:

Cell lysis
Secretion pathways
Stress responses during culture

Because HCPs vary depending on the cell line and process conditions, they are inherently complex and heterogeneous.

Why HCP Monitoring Is Important

Product Quality and Safety

Residual HCPs can:

Affect product stability
Trigger immune responses
Impact efficacy in some cases

For this reason, regulatory agencies expect robust monitoring and control of HCP levels in final products.

Process Development and Optimisation

Beyond final product testing, HCP monitoring is valuable earlier in development.

Changes in:

Culture conditions
Cell line selection
Downstream processing

can all influence HCP profiles. Monitoring these changes helps guide optimisation and improve overall process performance.

Understanding Clearance

HCP measurement is often used to evaluate:

Efficiency of purification steps
Consistency between batches
Performance of different process designs

This helps ensure that impurity levels are reduced effectively across the workflow.

HCP Analysis Methods

A range of analytical methods are used to monitor host cell proteins, each providing different types of information.

ELISA is most commonly used to measure total HCP levels, offering a relatively fast and scalable approach for routine monitoring.

Mass spectrometry, on the other hand, can be used to identify and track individual host cell proteins, providing more detailed insight into impurity profiles.

Because of the complexity of HCPs, these approaches are increasingly used as complementary methods. ELISA provides an overall measure of HCP burden, while mass spectrometry helps to characterise specific proteins that may persist through purification.

Together, they provide a more complete understanding of HCP behaviour across the development process.

Challenges in HCP Analysis

HCP analysis is inherently complex due to the nature of the impurities involved.

Unlike target proteins, HCPs represent a diverse mixture of proteins with different structures, abundances, and behaviours. This makes both detection and quantification more challenging.

A key limitation in commonly used methods is that HCP ELISA depends on antibody coverage. Polyclonal antibodies are designed to recognise a broad range of host cell proteins, but they may not fully represent the entire HCP population present in a sample. As a result, measured values can sometimes underestimate total HCP levels.

In addition, HCP profiles can vary depending on:

Cell line
Culture conditions
Process changes

This variability makes it important to interpret results within the context of the overall workflow, rather than relying on a single measurement alone.

HCP Monitoring Across the Workflow

HCP analysis is not limited to final product testing. It is used at multiple stages:

Upstream development
→ Comparing cell lines and conditions
Downstream processing
→ Evaluating purification efficiency
Final product characterisation
→ Ensuring regulatory compliance

The requirements at each stage are different, ranging from relative comparison to absolute quantification.

Supporting HCP Analysis in Practice

In many workflows, HCP ELISA remains the primary tool for quantifying total host cell protein levels.

At the same time, there is increasing interest in approaches that can support:

Faster feedback during development
More flexible measurement across samples
Integration into earlier-stage workflows

Platforms such as Amperia™ are being explored in this context to support protein quantification alongside traditional HCP assays.

Conclusion

Host cell proteins are an inherent part of biologics production, and their monitoring is critical for ensuring product quality and process robustness.

While established methods such as ELISA and mass spectrometry remain central, there is growing emphasis on integrating HCP analysis more effectively across development workflows—supporting faster iteration and better process understanding.